Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

被引：63
作者：
Gridelli, C [1 ]
Maione, P
Castaldo, V
Rossi, A
机构：
[1] SG Moscati Hosp Via Circumvallaz, Div Med Oncol, I-83100 Avellino, Italy
[2] SG Moscati Hosp Via Circumvallaz, Direz Sanitaria, I-83100 Avellino, Italy
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷 / 10期
关键词：
NSCLC; gefitinib; elderly; poor PS patients;
D O I：
10.1038/sj.bjc.6601387
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Elderly and poor performance status advanced non-small-cell lung cancer ( NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib ( Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.
引用
收藏
页码：1827 / 1829
页数：3
相关论文
共 11 条
  • [1] Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why?
    Bunn, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 23S - 33S
  • [2] Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
  • [3] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
    Fossella, FV
    DeVore, R
    Kerr, RN
    Crawford, J
    Natale, RR
    Dunphy, F
    Kalman, L
    Miller, V
    Lee, JS
    Moore, M
    Gandara, D
    Karp, D
    Vokes, E
    Kris, M
    Kim, Y
    Gamza, F
    Hammershaimb, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) : 2354 - 2362
  • [4] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    Fukuoka, M
    Yano, S
    Giaccone, G
    Tamura, T
    Nakagawa, K
    Douillard, JY
    Nishiwaki, Y
    Vansteenkiste, J
    Kudoh, S
    Rischin, D
    Eek, R
    Horai, T
    Noda, K
    Takata, I
    Smit, E
    Averbuch, S
    Macleod, A
    Feyereislova, A
    Dong, RP
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
  • [5] Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
    Gridelli, C
    Perrone, F
    Gallo, C
    Cigolari, S
    Rossi, A
    Piantedosi, F
    Barbera, S
    Ferraù, F
    Piazza, E
    Rosetti, F
    Clerici, M
    Bertetto, O
    Robbiati, SF
    Frontini, L
    Sacco, C
    Castiglione, F
    Favaretto, A
    Novello, S
    Migliorino, MR
    Gasparini, G
    Galetta, D
    Iaffaioli, RV
    Gebbia, V
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05): : 362 - 372
  • [6] Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
    Gridelli, C
    Gallo, C
    Shepherd, FA
    Illiano, A
    Piantedosi, F
    Robbiati, SF
    Manzione, L
    Barbera, S
    Frontini, L
    Veltri, E
    Findlay, B
    Cigolari, S
    Myers, R
    Ianniello, GP
    Gebbia, V
    Gasparini, G
    Fava, S
    Hirsh, V
    Beziak, A
    Seymour, L
    Perrone, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3025 - 3034
  • [7] Chemotherapy of non-small cell lung cancer in elderly patients
    Gridelli, C
    Maione, P
    Colantuoni, G
    Rossi, A
    [J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (16) : 1487 - 1495
  • [8] Herbst R., 2002, P AN M AM SOC CLIN, V21, P292
  • [9] MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
  • [10] 2-6
12